Access to revascularization among patients with acute myocardial infarction in New York City--impact of hospital resources.

PubWeight™: 0.80‹?›

🔗 View Article (PMC 3261287)

Published in J Urban Health on November 01, 2006

Authors

Jing Fang1, Abdissa Negassa, Robert W Gern, Michael H Alderman

Author Affiliations

1: Department of Epidemiology and Population Health, Albert Einstein College of Medicine, Bronx, NY 10461, USA. jfang@cdc.gov

Articles cited by this

Racial variation in cardiac procedure use and survival following acute myocardial infarction in the Department of Veterans Affairs. JAMA (1994) 5.03

Racial differences in the use of revascularization procedures after coronary angiography. JAMA (1993) 4.53

Long-term benefit of primary angioplasty as compared with thrombolytic therapy for acute myocardial infarction. N Engl J Med (1999) 3.81

Inequalities in access to coronary angiography and revascularisation: the association of deprivation and location of primary care services. Br J Gen Pract (2000) 2.01

Angioplasty vs thrombolysis for acute myocardial infarction: a quantitative overview of the effects of interhospital transportation. Eur Heart J (2003) 1.97

High-technology cardiac procedures. The impact of service availability on service use in New York State. JAMA (1993) 1.76

Race and sex differences in the management of coronary artery disease. Am Heart J (2000) 1.74

Long-term MI outcomes at hospitals with or without on-site revascularization. JAMA (2001) 1.66

Waiting times, revascularization modality, and outcomes after acute myocardial infarction at hospitals with and without on-site revascularization facilities in Canada. J Am Coll Cardiol (2003) 1.58

Access to hospitals with high-technology cardiac services: how is race important? Am J Public Health (1995) 1.14

Primary coronary angioplasty compared with intravenous thrombolytic therapy for acute myocardial infarction: six-month follow up and analysis of individual patient data from randomized trials. Am Heart J (2003) 1.12

Sequential events contributing to variations in cardiac revascularization rates. Med Care (1995) 1.10

Early and midterm results after coronary artery bypass grafting with and without cardiopulmonary bypass: which patient population benefits the most? Heart Surg Forum (2003) 1.05

Is geography destiny for patients in New York with myocardial infarction? Am J Med (2003) 0.95

Understanding racial differences in cardiovascular care and outcomes: issues for the new millennium. Am Heart J (2000) 0.92

Clinical trials in acute myocardial infarction. Curr Opin Cardiol (1999) 0.83

Articles by these authors

(truncated to the top 100)

Statistical analysis of correlated data using generalized estimating equations: an orientation. Am J Epidemiol (2003) 15.06

Health outcomes associated with various antihypertensive therapies used as first-line agents: a network meta-analysis. JAMA (2003) 7.42

Success and predictors of blood pressure control in diverse North American settings: the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT). J Clin Hypertens (Greenwich) (2002) 6.03

Sodium intake and mortality in the NHANES II follow-up study. Am J Med (2006) 3.24

Rationale and design for the blood pressure intervention of the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial. Am J Cardiol (2007) 3.10

The impact of serum uric acid on cardiovascular outcomes in the LIFE study. Kidney Int (2004) 2.96

Prognostic importance of weight loss in chronic heart failure and the effect of treatment with angiotensin-converting-enzyme inhibitors: an observational study. Lancet (2003) 2.10

ALLHAT findings revisited in the context of subsequent analyses, other trials, and meta-analyses. Arch Intern Med (2009) 2.02

Sodium intake and mortality follow-up in the Third National Health and Nutrition Examination Survey (NHANES III). J Gen Intern Med (2008) 1.79

Clinical events in high-risk hypertensive patients randomly assigned to calcium channel blocker versus angiotensin-converting enzyme inhibitor in the antihypertensive and lipid-lowering treatment to prevent heart attack trial. Hypertension (2006) 1.73

Conjugated equine estrogen and risk of benign proliferative breast disease: a randomized controlled trial. J Natl Cancer Inst (2008) 1.72

A call for higher standards of evidence for dietary guidelines. Am J Prev Med (2008) 1.69

Effect of physician volume on the relationship between hospital volume and mortality during primary angioplasty. J Am Coll Cardiol (2009) 1.67

Choice of clinical outcomes in randomized trials of heart failure therapies: disease-specific or overall outcomes? Am Heart J (2002) 1.64

Acute myocardial infarction hospitalization in the United States, 1979 to 2005. Am J Med (2010) 1.63

Renin-angiotensin system blockers may create more risk than reward for sodium-depleted cardiovascular patients with high plasma renin levels. Am J Hypertens (2013) 1.57

Hypertension control at physicians' offices in the United States. Am J Hypertens (2008) 1.56

Renal dysfunction and ischemic heart disease mortality in a hypertensive population. J Hypertens (2005) 1.55

Is high pulse pressure a marker of preclinical cardiovascular disease? Hypertension (2005) 1.53

Randomized phase II trial of embolization therapy versus chemoembolization therapy in previously treated patients with colorectal carcinoma metastatic to the liver. Clin Colorectal Cancer (2002) 1.48

Targeting insulin inhibition as a metabolic therapy in advanced cancer: a pilot safety and feasibility dietary trial in 10 patients. Nutrition (2012) 1.39

A multi-center prospective cohort study of benign breast disease and risk of subsequent breast cancer. Cancer Causes Control (2010) 1.35

Enduring direct association of baseline plasma renin activity with all-cause and cardiovascular mortality in hypertensive patients. Am J Hypertens (2011) 1.27

Blood-pressure-related disease is a global health priority. Lancet (2008) 1.22

Validation of the histologic risk model in a new cohort of patients with head and neck squamous cell carcinoma. Am J Surg Pathol (2010) 1.20

Characteristics of children with primary hypertension seen at a referral center. Pediatr Nephrol (2005) 1.15

The effects of vitamin D repletion on endothelial function and inflammation in patients with coronary artery disease. Vasc Med (2012) 1.13

Clinical efficacy and survival with first-line inhaled iloprost therapy in patients with idiopathic pulmonary arterial hypertension. Eur Heart J (2005) 1.13

Exercise, body mass index, caloric intake, and cardiovascular mortality. Am J Prev Med (2003) 1.10

Effect of viral upper respiratory tract infection on the urge-to-cough sensation. Respir Med (2010) 1.09

Variations in hip fracture hospitalization rates among different race/ethnicity groups in New York City. Ethn Dis (2004) 1.08

Differential use of coronary revascularization and hospital mortality following acute myocardial infarction. Arch Intern Med (2003) 1.05

Mortality and morbidity during and after the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial. J Clin Hypertens (Greenwich) (2011) 1.04

Impact of the increasing burden of diabetes on acute myocardial infarction in New York City: 1990-2000. Diabetes (2006) 1.02

Declining US stroke hospitalization since 1997: National Hospital Discharge Survey, 1988-2004. Neuroepidemiology (2008) 1.01

Trends in acute myocardial infarction complicated by cardiogenic shock, 1979-2003, United States. Am Heart J (2006) 1.00

Phase II trial of tipifarnib plus neoadjuvant doxorubicin-cyclophosphamide in patients with clinical stage IIB-IIIC breast cancer. Clin Cancer Res (2009) 1.00

Cardiovascular risk reduction in hypertensive black patients with left ventricular hypertrophy: the LIFE study. J Am Coll Cardiol (2004) 0.99

Clinical characteristics of stroke among Chinese in New York City. Ethn Dis (2004) 0.99

Dissociation of hospitalization and mortality trends for myocardial infarction in the United States from 1988 to 1997. Am J Med (2002) 0.98

Validation of the risk model: high-risk classification and tumor pattern of invasion predict outcome for patients with low-stage oral cavity squamous cell carcinoma. Head Neck Pathol (2012) 0.98

Role of family history and ethnicity on the mode and age of prostate cancer presentation. Prostate (2002) 0.96

Sodium and cardiovascular disease. N Engl J Med (2014) 0.95

Is geography destiny for patients in New York with myocardial infarction? Am J Med (2003) 0.95

A randomized controlled trial of calcium plus vitamin D supplementation and risk of benign proliferative breast disease. Breast Cancer Res Treat (2008) 0.95

Sodium, blood pressure, and cardiovascular disease. Curr Opin Cardiol (2007) 0.94

Novel yeast-based strategy unveils antagonist binding regions on the nuclear xenobiotic receptor PXR. J Biol Chem (2013) 0.93

Effect of tiotropium on cough reflex sensitivity in acute viral cough. Lung (2008) 0.93

Vascular disease among hospitalized multiple sclerosis patients. Neuroepidemiology (2008) 0.93

Beyond hypertension toward guidelines for cardiovascular risk reduction. Am J Hypertens (2004) 0.92

Radiofrequency ablation of advanced head and neck cancer. Arch Otolaryngol Head Neck Surg (2011) 0.92

The role of Ink4a/Arf in ErbB2 mammary gland tumorigenesis. Cancer Res (2003) 0.91

Combining neurohormonal blockade with continuous-flow left ventricular assist device support for myocardial recovery: a single-arm prospective study. J Heart Lung Transplant (2013) 0.90

Persistent sex difference in hospital outcome following percutaneous coronary intervention: results from the New York State reporting system. J Invasive Cardiol (2007) 0.89

Estrogen plus progestin and risk of benign proliferative breast disease. Cancer Epidemiol Biomarkers Prev (2008) 0.86

Low-fat dietary pattern and risk of benign proliferative breast disease: a randomized, controlled dietary modification trial. Cancer Prev Res (Phila) (2008) 0.83

High prevalence of high grade anal intraepithelial neoplasia in HIV-infected women screened for anal cancer. J Acquir Immune Defic Syndr (2012) 0.83

Heart transplantation in heart failure: the prognostic importance of body mass index at time of surgery and subsequent weight changes. Eur J Heart Fail (2007) 0.83

Modeling the time dependence of the association between human papillomavirus infection and cervical cancer precursor lesions. Am J Epidemiol (2003) 0.83

The Cochrane review of sodium and health. Am J Hypertens (2011) 0.83

Phase I trial of metronomic oral vinorelbine in patients with advanced cancer. Cancer Chemother Pharmacol (2011) 0.83

Gender differences of revascularization in patients with acute myocardial infarction. Am J Cardiol (2006) 0.82

Investigation of the urge-to-cough sensation in healthy volunteers. Respirology (2012) 0.82

Exercise and cardiovascular outcomes by hypertensive status: NHANES I epidemiological follow-up study, 1971-1992. Am J Hypertens (2005) 0.82

The Mayo Clinic Risk Score predicts in-hospital mortality following primary angioplasty. J Invasive Cardiol (2005) 0.82

Quality of life in hypertensive patients: does it matter and should we measure it? J Hypertens (2005) 0.82

Stroke risk among Chinese immigrants in New York City. J Immigr Minor Health (2006) 0.81

Dietary Sodium and Cardiovascular Disease Risk. N Engl J Med (2016) 0.81

Blood-pressure-related disease is a global health priority. Am J Hypertens (2008) 0.80

Risk factors for breast cancer in women biopsied for benign breast disease: a nested case-control study. Cancer Epidemiol (2010) 0.80

Mortality and readmission rates in patients hospitalized for acute decompensated heart failure: a comparison between cardiology and general-medicine service outcomes in an underserved population. Clin Cardiol (2015) 0.79

Podagra, uric acid, and cardiovascular disease. Circulation (2007) 0.79

Blood-pressure-related disease is a global health priority. J Hypertens (2008) 0.79

Does blood pressure control require a Cuban-style revolution? J Hypertens (2006) 0.78

Resistant hypertension: a clinical syndrome in search of a definition. Am J Hypertens (2008) 0.78

A Cohort Study of p53 Mutations and Protein Accumulation in Benign Breast Tissue and Subsequent Breast Cancer Risk. J Oncol (2011) 0.78

Global proteomic analysis distinguishes biologic differences in head and neck squamous carcinoma. Lab Invest (2007) 0.78

A phase I-II study of the histone deacetylase inhibitor vorinostat plus sequential weekly paclitaxel and doxorubicin-cyclophosphamide in locally advanced breast cancer. Breast Cancer Res Treat (2014) 0.78

Phase I trial of infusional cyclophosphamide, doxorubicin, and etoposide plus granulocyte-macrophage colony stimulating factor (GM-CSF) in non-Hodgkin's lymphoma. Med Oncol (2005) 0.78

Phase II study of weekly docetaxel alone or in combination with trastuzumab in patients with metastatic breast cancer. Clin Breast Cancer (2004) 0.77

Hypertension control: improved, but not enough! Am J Hypertens (2007) 0.77

The return on INVEST. JAMA (2003) 0.76

Does supplemental private insurance affect care of Medicare recipients hospitalized for myocardial infarction? Am J Public Health (2004) 0.75

Blood pressure measures, relative and absolute risk, and international differences. J Hypertens (2002) 0.75

Hypertension in sub-Saharan Africa: what physicians can do! Am J Hypertens (2009) 0.75

MEDULLARY THYROID CANCER THAT STAINS NEGATIVE FOR CA 19-9 HAS DECREASED METASTATIC POTENTIAL. Endocr Pract (2015) 0.75

Salt: data and speculation. Clin Auton Res (2002) 0.75

More about plasma renin and cardiovascular mortality. Eur Heart J (2011) 0.75

Hypertension, silver bullets and faded dreams. J Hypertens (2004) 0.75

Risk of hospitalized gastrointestinal bleeding in persons randomized to diuretic, ACE-inhibitor, or calcium-channel blocker in ALLHAT. J Clin Hypertens (Greenwich) (2013) 0.75

Estimation of death rates from pandemic influenza. Lancet (2007) 0.75

ALLHAT and beyond. Am J Hypertens (2003) 0.75

Dietary salt and cardiovascular disease. Lancet (2011) 0.75

Hypertension control and kidney disease: some questions answered, many remain. JAMA (2002) 0.75

Glucose-cholesterol interaction magnifies coronary heart disease risk for hypertensive patients. Hypertension (2004) 0.75

Randomized clinical trials: prescriptions to be applied with caution! Am J Hypertens (2008) 0.75

Editor's Note. The Renin-Angiotensin System: Today and Tomorrow in Research and Clinical Practice. Am J Hypertens (2011) 0.75

Clinical problems in the management of hypertension 1) Prehypertension: should we treat? 2)The very elderly: how should we treat. J Clin Hypertens (Greenwich) (2004) 0.75

Effectiveness of glycoprotein IIb/IIIa inhibitor use during primary coronary angioplasty: results of propensity analysis using the New York State Percutaneous Coronary Intervention Reporting System. Am J Cardiol (2006) 0.75

How much effect of different antihypertensive medications on cardiovascular outcomes is attributable to their effects on blood pressure? Stat Med (2012) 0.75